This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Jul;115(7):21.

doi: 10.1097/01.NAJ.0000467267.67704.e1.

Haloperidol vs. Low-Potency Antipsychotic Drugs for Schizophrenia

Teresa L Bryan¹

Affiliations

Affiliation

¹ Teresa L. Bryan is an assistant professor and coordinator of graduate programs at Alcorn State University, Natchez, MS, and a member of the Cochrane Nursing Care Field.

PMID: 26110946
DOI: 10.1097/01.NAJ.0000467267.67704.e1

Comment

Haloperidol vs. Low-Potency Antipsychotic Drugs for Schizophrenia

Teresa L Bryan. Am J Nurs. 2015 Jul.

. 2015 Jul;115(7):21.

doi: 10.1097/01.NAJ.0000467267.67704.e1.

Author

Teresa L Bryan¹

Affiliation

¹ Teresa L. Bryan is an assistant professor and coordinator of graduate programs at Alcorn State University, Natchez, MS, and a member of the Cochrane Nursing Care Field.

PMID: 26110946
DOI: 10.1097/01.NAJ.0000467267.67704.e1

No abstract available

PubMed Disclaimer

Comment on

Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.
Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Tardy M, et al. Cochrane Database Syst Rev. 2014 Jul 9;2014(7):CD009268. doi: 10.1002/14651858.CD009268.pub2. Cochrane Database Syst Rev. 2014. PMID: 25007358 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Medical
- MedlinePlus Health Information